Genomic Vision (Genomic) is a molecular diagnostics company that develops and commercializes diagnostic tests for genetic diseases and cancers. The company’s portfolio comprises tests for breast cancer and colon cancer; diagnostic solution for facio-scapulo-humeral muscular dystrophy; and tools for identifying and characterizing rearrangements which affect the BRCA1 and BRCA2 genes. Its diagnostic tests are based based on DNA molecular combing technology. The DNA molecular combing technology facilitates the direct visualization of individual DNA molecules and helps in discovery and analysis of new structural variations that are potentially involved in disease. The company’s technology finds application in monitoring both spatial and temporal characteristics of DNA replication in a single experiment and identification of structural variations, at any position within the genome. Its conducts research studies on large genomic rearrangements and their involvement in cancer and genetic disorders to develop new assays for in vitro diagnostics and biomarker discovery. Genomic is headquartered in Bagneux, France.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Genomic Vision
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio